BioCentury | Sep 22, 2014
Strategy

Weighing in on obesity

...leaf (lemon balm) ethyl acetate dried extract Ph III (complete 2015) Orexigen Therapeutics Inc. (NASDAQ:OREX) Empatic...
BioCentury | Mar 25, 2013
Clinical News

Empatic regulatory update

...Orexigen disclosed in its 4Q12 earnings that FDA said Phase III data for obesity candidate Empatic...
...as long as the placebo-subtracted changes in body weight, blood pressure and heart rate for Empatic...
...to entering Phase III testing. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Product: Empatic ( zonisamide SR/bupropion SR...
BioCentury | Apr 2, 2012
Finance

Thinking small again

...efficacy among the obesity candidates that have been reviewed once by FDA. Orexigen's backup is Empatic...
BioCentury | Jun 6, 2011
Regulation

Obesity double standard

...days to respond. Besides Contrave, Orexigen has just one other clinical candidate, also for obesity. Empatic...
BioCentury | Jun 6, 2011
Clinical News

Contrave regulatory update

...well as opportunities to develop its obesity programs outside the U.S. Orexigen is also developing Empatic...
BioCentury | Jun 3, 2011
Top Story

Orexigen falls on Contrave update

...well as opportunities to develop its obesity programs outside the U.S. Orexigen is also developing Empatic...
BioCentury | Feb 7, 2011
Product Development

Obesity Reset

...Histalean (formerly OBE101) Anti-obesity compound comprised of betahistine Ph II (A) Orexigen Therapeutics Inc. (NASDAQ:OREX) Empatic...
BioCentury | Sep 6, 2010
Strategy

A fatter deal wasn't needed

...in hopes of getting a bigger upfront payment made little sense. Orexigen's following program is Empatic...
BioCentury | Oct 12, 2009
Clinical News

Empatic zonisamide SR/bupropion SR: Phase IIb data

...In the double-blind, U.S. Phase IIb ZB-202 trial in 636 patients, both doses of Empatic met...
...vs. bupropion alone and vs. placebo. Specifically, mean weight loss was 7.5% for high dose Empatic...
...cognitive function, depression, suicidality or anxiety. Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Product: Empatic zonisamide SR/bupropion SR...
BioCentury | Oct 5, 2009
Analyst Picks & Changes

Analysts Picks & Changes

...$10 after Orexigen reported that in a U.S. Phase IIb trial both dose levels of Empatic...
Items per page:
1 - 10 of 38